Pfizer Vaccines: A Budding Portfolio Of Long-Term Opportunities
Executive Summary
Pfizer sees long-term growth potential in vaccines, fueled by new products targeted to patients across their life, from unborn children to seniors, including a portfolio of vaccines targeted to pregnant women and therapeutic cancer vaccines.
You may also be interested in...
Pfizer Persists: Big Opportunities And Challenges In Vaccines
The big pharma has two vaccines that have progressed to late-stage development, one for Clostridium difficile infection and the other for Staph aureus. Both represent big commercial opportunities, but bringing a new vaccine to market is a slow process.
Pfizer's Staph Vaccine: Can Narrow Trial Population Support Broader Claim?
US FDA advisory committee will weigh in on clinical development plan for SA4Ag, an S. aureus vaccine for prophylactic use, including whether safety and efficacy data from an ongoing, Phase II trial in spinal surgery patients are generalizable to other elective orthopedic surgical populations.
Pfizer Oncology Strategy: An Investment Starts To Pay Off
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.